The U.S. Food & Drug Administration (FDA) recently approved a new version of a current diabetes medication called Mounjaro to be used for weight management. It is meant for use by people who have a health condition related to obesity, such as high blood pressure or type 2 diabetes. The new injectable drug is called Zepbound and should be used in combination with a healthy diet and exercise.

On November 8, 2023 the FDA approved a new version of the current diabetes drug Mounjaro for use in weight management for people who have a medical condition related to obesity.

The active ingredient in both Mounjaro and Zepbound is tirzepatide, and it works by activating hormone receptors in the intestine that help reduce appetite.

The medication is administered by an injection once a week, and is meant to be used in combination with a healthy diet and exercise.

The medication does slow down digestion and can lead to stomach and intestinal side effects. Patients should talk with their doctor about all potential risks and side effects to decide if Zepbound is right for them.

Zepbound is only available with a prescription, but it may not be covered by insurance companies who do not reimburse for weight loss management.

The safety of this medication has only been studied for people with obesity; it is not considered safe for people who are not obese and do not have a weight-related health condition.

There is a nationwide shortage of some weight loss medications. It is unclear how this will affect the availability of Zepbound.